Seres Therapeutics Inc (NASDAQ:MCRB) — Market Cap & Net Worth
Market Cap & Net Worth: Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc (NASDAQ:MCRB) has a market capitalization of $60.82 Million ($60.82 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21204 globally and #4696 in its home market, demonstrating a 2.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seres Therapeutics Inc's stock price $6.46 by its total outstanding shares 9683934 (9.68 Million). Review Seres Therapeutics Inc (MCRB) total liabilities to assess the company's total debt and financial obligations.
Seres Therapeutics Inc Market Cap History: 2015 to 2026
Seres Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $339.81 Million to $62.56 Million (-13.80% CAGR).
Index Memberships
Seres Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #608 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2036 of 3165 |
Weight: Seres Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Seres Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seres Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
182.63x
Seres Therapeutics Inc's market cap is 182.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.30x
Seres Therapeutics Inc's market cap is 25.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $95.87 Million | $21.77 Million | -$91.58 Million | 4.40x | N/A |
| 2017 | $98.20 Million | $32.10 Million | -$89.38 Million | 3.06x | N/A |
| 2018 | $43.77 Million | $28.27 Million | -$98.94 Million | 1.55x | N/A |
| 2019 | $33.41 Million | $34.51 Million | -$70.28 Million | 0.97x | N/A |
| 2020 | $237.26 Million | $33.22 Million | -$89.13 Million | 7.14x | N/A |
| 2021 | $80.67 Million | $144.93 Million | -$65.58 Million | 0.56x | N/A |
| 2022 | $54.23 Million | $7.13 Million | -$250.16 Million | 7.61x | N/A |
| 2023 | $13.56 Million | $126.33 Million | -$113.72 Million | 0.11x | N/A |
| 2025 | $144.10 Million | $789.00K | $5.70 Million | 182.63x | 25.30x |
Competitor Companies of MCRB by Market Capitalization
Companies near Seres Therapeutics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Seres Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Seres Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Seres Therapeutics Inc's market cap moved from $339.81 Million to $ 62.56 Million, with a yearly change of -13.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $62.56 Million | -56.59% |
| 2025 | $144.10 Million | +1690.61% |
| 2024 | $8.05 Million | -40.64% |
| 2023 | $13.56 Million | -75.00% |
| 2022 | $54.23 Million | -32.77% |
| 2021 | $80.67 Million | -66.00% |
| 2020 | $237.26 Million | +610.14% |
| 2019 | $33.41 Million | -23.67% |
| 2018 | $43.77 Million | -55.42% |
| 2017 | $98.20 Million | +2.42% |
| 2016 | $95.87 Million | -71.79% |
| 2015 | $339.81 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Seres Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.82 Million USD |
| MoneyControl | $60.82 Million USD |
| MarketWatch | $60.82 Million USD |
| marketcap.company | $60.82 Million USD |
| Reuters | $60.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more